<DOC>
	<DOCNO>NCT00354380</DOCNO>
	<brief_summary>The primary objective trial study safety combination methylene blue ( MB ) -artesunate ( AS ) MB-amodiaquine ( AQ ) treat malaria among child compare safety AS-AQ regimen . The secondary objective investigate efficacy MB-AS MB-AQ .</brief_summary>
	<brief_title>Safety Efficacy Methylene Blue Combined With Artesunate Amodiaquine Malaria Treatment Children Burkina Faso : Pilot Study</brief_title>
	<detailed_description>Objectives : The primary objective trial study safety combination methylene blue ( MB ) -artesunate ( AS ) MB-amodiaquine ( AQ ) give three day 6-10 year old child uncomplicated falciparum malaria malaria endemic area compare safety three day AS-AQ regimen . Secondary objective investigate efficacy MB-AS MB-AQ . Population : Children age 6-10 year uncomplicated malaria Nouna town . Sample size : N= 180 ( n=60 group ) . Treatment : The participant MB-AS group receive orally twice daily 9mg/kg MB combine daily 4mg/kg AS 3 day . The participant MB-AQ group receive orally twice daily 9mg/kg MB combine daily 10mg/kg AQ 3 day . The participant comparator group receive 3 day regimen daily oral AS ( 4mg/kg ) combine daily AQ ( 10mg/kg ) . Endpoints : The primary endpoint number adverse event ( AE ) drug intake day 28 . Secondary endpoint number serious adverse event ( SAE ) , adequate clinical parasitological response ( ACPR ) rate day 28 , clinical parasitological failure rate day 3 , 7 , 14 28 , change haematocrit day 28 , fever parasite clearance time .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Inclusion criterion : 610 year old child Ability swallow tablet Uncomplicated malaria cause P. falciparum Asexual parasites ≥ 2000/µl &lt; 200000/µl Axillary temperature ≥ 37.5°C Burkinabe nationality Informed consent Complicated severe malaria Any apparent significant disease Anaemia ( haematocrit &lt; 21 % ) Treated trial Antimalarial treatment prior inclusion ( last three day ) , except child treat chloroquine</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Africa</keyword>
	<keyword>Methalyne-blue</keyword>
	<keyword>Artesunate</keyword>
	<keyword>Amodiaquine</keyword>
</DOC>